Protocol number: APD334-301A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis. ARENA APD334-301. Lilly, Sub-Investigator - Faz 3